摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-amino-2,6-difluoro-phenyl)-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone | 1254567-36-6

中文名称
——
中文别名
——
英文名称
(3-amino-2,6-difluoro-phenyl)-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone
英文别名
(3-amino-2,6-difluorophenyl)-[5-(2-methoxypyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]methanone
(3-amino-2,6-difluoro-phenyl)-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone化学式
CAS
1254567-36-6
化学式
C19H13F2N5O2
mdl
——
分子量
381.341
InChiKey
NMHBEUFZCXTXOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    107
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    (3-amino-2,6-difluorophenyl)(5-iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone 、 2-甲氧基-5-嘧啶硼酸(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 silica gel 、 二氯甲烷 作用下, 以 potassium carbonate乙腈 为溶剂, 反应 0.25h, 以to provide the desired compound (21, 0.567 g)的产率得到(3-amino-2,6-difluoro-phenyl)-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone
    参考文献:
    名称:
    Compounds and Methods for Kinase Modulation, and Indications Therefor
    摘要:
    本文描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中,所述化合物或其盐、配方、共轭物、衍生物和形式对BRaf和c-Raf-1蛋白激酶都具有活性,并且还可能对A-Raf和B-Raf V600E蛋白激酶中的任何一个或两个都具有活性。还描述了使用它们治疗疾病和病况的方法,包括黑色素瘤、结肠直肠癌、甲状腺癌、卵巢癌和胆道癌。
    公开号:
    US20100286142A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES<br/>[FR] DÉRIVÉS DE PYRROLO [2, 3-B] PYRIDINE POUR L'INHIBITION DES KINASES RAF
    申请人:PLEXXIKON INC
    公开号:WO2010104945A1
    公开(公告)日:2010-09-16
    Propane-1-sulfonic acid 2,4-difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide, pyrrolidine-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, N,N-dimethylamino-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, glioma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, and biliary tract cancer.
    描述了丙烷-1-磺酸2,4-二氟-3-[5-(2-甲氧基嘧啶-5-基)-1H-吡咯并[2,3-b]吡啶-3-甲酰基]-苯基}-酰胺,丙烷-1-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2,4-二氟-苯基]-酰胺,丙烷-1-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2-氟-苯基]-酰胺,N-[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2,4-二氟-苯基]-2,5-二氟-苯磺酰胺,N-[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2,4-二氟-苯基]-3-氟-苯磺酰胺,吡咯烷-1-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2,4-二氟-苯基]-酰胺,N,N-二甲基胺基-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-甲酰基)-2,4-二氟-苯基]-酰胺及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中,所述化合物或其盐、配方、共轭物、衍生物和形式至少对一种Raf蛋白激酶具有活性。还描述了利用这些方法治疗与Raf蛋白激酶活性相关的疾病和症状的方法,包括黑色素瘤、胶质瘤、结肠直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌和胆道癌等疾病和症状。
  • Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
    申请人:IP Gesellschaft für Management mbH
    公开号:EP2815749A1
    公开(公告)日:2014-12-24
    The invention relates to a packaging comprising one or more administration units comprising a solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione.
    该发明涉及一种包装,其中包括一个或多个包含4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮固体形式的给药单元。
  • [EN] PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE<br/>[FR] PYRROLO [2, 3. B] PYRIDINES QUI INHIBENT LA PROTÉINE KINASE RAF
    申请人:PLEXXIKON INC
    公开号:WO2010129567A1
    公开(公告)日:2010-11-11
    Compounds (I) and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf -1 protein kinase, and may also be active on either or both of A-Raf and B-Raf V600E protein kinase. Also described are methods of use thereof to treat diseases and conditions, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, and biliary tract cancer.
    描述了化合物(I)及其盐,配方,结合物,衍生物,形式和用途。在某些方面和实施例中,所述的化合物或其盐,配方,结合物,衍生物和形式对BRaf和c-Raf -1蛋白激酶均具有活性,并且也可能对A-Raf和B-Raf V600E蛋白激酶中的一个或两个具有活性。还描述了使用这些方法来治疗疾病和病况,包括黑色素瘤,结直肠癌,甲状腺癌,卵巢癌和胆道癌。
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    申请人:Plexxikon Inc.
    公开号:US20170157120A1
    公开(公告)日:2017-06-08
    Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    描述了对蛋白激酶活性有影响的化合物,以及制备和使用这些化合物来治疗与蛋白激酶异常活性相关的疾病和症状的方法。
  • [EN] SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS<br/>[FR] FORMES SOLIDES DE SULFONAMIDES ET D'ACIDES AMINÉS
    申请人:PLEXXIKON INC
    公开号:WO2010129570A1
    公开(公告)日:2010-11-11
    Solid forms of phenyl sulfonamide compounds of formula (I) active on protein kinases, including Raf protein kinases, are described, as well as methods of using such solid forms to treat diseases and conditions associated with activity of protein kinases, e.g. Raf protein kinases, including pain, polycystic kidney disease, melanoma and colorectal cancer.
    本文描述了公式(I)的苯基磺酰胺化合物的固体形式,其在蛋白激酶中具有活性,包括Raf蛋白激酶,以及使用这些固体形式治疗与蛋白激酶活性相关的疾病和病况的方法,例如疼痛、多囊肾病、黑色素瘤和结直肠癌。
查看更多